Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Journal:
Current Drug Safety
Volume:
5
Page:
171-181
Author(s):
Adam Cuker, Elaine Y. Chiang and Douglas B. Cines
Cell Cycle as a Target of Antineoplastic Drugs
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1417-1426
Author(s):
Maria De Falco and Antonio De Luca
Adverse Effects and Drug Interactions of Biologic Agents
Journal:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume:
9
Page:
46-53
Author(s):
Yasemin Turan
Future Prospect of RNA Interference for Cancer Therapies
Journal:
Current Drug Targets
Volume:
11
Page:
345-360
Author(s):
Eishi Ashihara, Eri Kawata and Taira Maekawa
Silibinin – A Promising New Treatment for Cancer
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
10
Page:
186-195
Author(s):
Catherine Wing Ying Cheung, Norma Gibbons, David Wayne Johnson and David Lawrence Nicol
Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1040-1054
Author(s):
Kathlynn C. Brown
Toll-Like Receptors: Cost or Benefit for Cancer?
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1081-1090
Author(s):
T. Matijevic and J. Pavelic
Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
229-241
Author(s):
Lunyin Yu, Hari G. Garg, Boyangzi Li, Robert J. Linhardt and Charles A. Hales
Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
Journal:
CNS & Neurological Disorders - Drug Targets
Volume:
9
Page:
120-127
Author(s):
Sarah Burgess and Valentina Echeverria
Glycomics: Relevance for Personalized Medicine
Journal:
Current Pharmacogenomics and Personalized Medicine
Volume:
8
Page:
49-63
Author(s):
C.-H. Liang and C.-Y. Wu